Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEP) EBIT (2021 - 2025)

Historic EBIT for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to -$2.5 million.

  • Coeptis Therapeutics Holdings' EBIT fell 1565.23% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 1740.23%. This contributed to the annual value of -$10.1 million for FY2024, which is 5321.56% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported EBIT of -$2.5 million as of Q3 2025, which was down 1565.23% from -$4.5 million recorded in Q2 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' EBIT peaked at -$141518.0 during Q1 2021, and registered a low of -$15.7 million during Q1 2022.
  • Moreover, its 5-year median value for EBIT was -$3.5 million (2023), whereas its average is -$4.8 million.
  • As far as peak fluctuations go, Coeptis Therapeutics Holdings' EBIT plummeted by 1100481.71% in 2022, and later surged by 7289.29% in 2024.
  • Quarter analysis of 5 years shows Coeptis Therapeutics Holdings' EBIT stood at -$141518.0 in 2021, then plummeted by 2050.45% to -$3.0 million in 2022, then fell by 10.6% to -$3.4 million in 2023, then skyrocketed by 35.76% to -$2.2 million in 2024, then dropped by 14.56% to -$2.5 million in 2025.
  • Its last three reported values are -$2.5 million in Q3 2025, -$4.5 million for Q2 2025, and -$4.1 million during Q1 2025.